Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
暂无分享,去创建一个
Y. Menda | J. Babich | D. Bushnell | T. O'Dorisio | M. O'dorisio | M. Madsen | G. Khanna | M. Connolly | S. Kao | Stacy Michael | S. Michael
[1] Marion de Jong,et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. , 2010, Endocrine-related cancer.
[2] R. Bale,et al. 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy , 2009, Journal of Nuclear Medicine.
[3] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Krenning,et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Brian J. Smith,et al. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies , 2008, Pediatric blood & cancer.
[6] P. Pandolfi,et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. , 2008, Genes & development.
[7] T. MacDonald,et al. Medulloblastoma in childhood: new biological advances , 2007, The Lancet Neurology.
[8] R. Valkema,et al. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. , 2007, Hematology/oncology clinics of North America.
[9] Glenn D. Flux,et al. Dosimetry for 90Y-DOTATOC therapies in patients with neuroendocrine tumors , 2007 .
[10] E. Krenning,et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[11] G. Videtic,et al. Primary carcinoid tumors of the lung: a role for radiotherapy. , 2006, Oncology.
[12] E. Krenning,et al. Somatostatin receptor imaging for neuroendocrine tumors , 2006, Pituitary.
[13] Su-Chun Cheng,et al. Tumor response and toxicity with multiple infusions of high dose 131I‐MIBG for refractory neuroblastoma , 2005, Pediatric blood & cancer.
[14] P. Bartenstein,et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[15] H. Jürgens,et al. Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging , 2004, Clinical Cancer Research.
[16] J. Dickson,et al. Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging , 2004, Nuclear medicine communications.
[17] Y. Menda,et al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] M. Konijnenberg,et al. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? , 2003, Cancer biotherapy & radiopharmaceuticals.
[19] D. Stram,et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. , 2003, International journal of radiation oncology, biology, physics.
[20] M. Cremonesi,et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[21] H. Herzog,et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide , 2001, European Journal of Nuclear Medicine.
[22] J. Rivier,et al. Somatostatin receptor gene expression in neuroblastoma , 2000, Regulatory Peptides.
[23] R. Herrmann,et al. Yttrium-90 DOTATOC: first clinical results , 1999, European Journal of Nuclear Medicine.
[24] T. Pietsch,et al. High Expression of Somatostatin Receptor Subtype 2 (sst2) in Medulloblastoma: Implications for Diagnosis and Therapy , 1999, Pediatric Research.
[25] E. Krenning,et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] J. Mueller‐Brand,et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment , 1998, The Lancet.
[27] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[28] M. Relling,et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.
[30] Herbert Malamud,et al. MIRD Primer for Absorbed Dose Calculations , 1989 .
[31] Fynn Rw. One hundred years after. , 1959 .
[32] Y. Menda,et al. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] Giovanni Paganelli,et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] Marion de Jong,et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] R. Valkema,et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[36] J. Laissue,et al. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.
[37] M G Stabin,et al. Absorbed fractions for electrons and beta particles in spheres of various sizes. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] Thomas F. Budinger,et al. MIRD primer for absorbed dose calculations , 1988 .